The year 2022 so far has seen fewer mergers in certain industries, such as healthcare, as a result of high valuations and skepticism surrounding antitrust investigations.  Big drugmakers are recording revenue losses on the verge of patents’ expiry, and as a result, proceeding toward merger deals to strengthen their pipeline and portfolios.   Merck (NYSE: MRK) is one such healthcare company that contemplates valuable deals to focus on sectors like cancer, vaccines, and animal health. According to a recent Wall Street Journal report, Merck is in discussions to purchase cancer-focused biotech firm Seagen Inc. (SGEN), which has a market capitalization of $30.46 billion.
https://www.tipranks.com/news/will-merck-acquire-seagen?utm_source=advfn.com&utm_medium=referral